Cannabis use and the mental health of young people

Australian and New Zealand Journal of Psychiatry

Volumn 40, Issue 2, 2006, Pages 105-113

  Hall, Wayne D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Adolescence; Cannabis use; Dependence; Marijuana smoking; Psychosis

Indexed keywords

ALCOHOL; CANNABIS; COCAINE; DIAMORPHINE; ILLICIT DRUG; NICOTINE; OPIATE DERIVATIVE;

ADOLESCENCE; CANNABIS ADDICTION; COCAINE DEPENDENCE; COMMUNITY CARE; DEVELOPED COUNTRY; EDUCATION; EPIDEMIOLOGICAL DATA; GENETIC SUSCEPTIBILITY; HEALTH CARE POLICY; HEROIN DEPENDENCE; HUMAN; LONGITUDINAL STUDY; MEDLINE; NONHUMAN; PREDICTION; PSYCHOSIS; PSYCHOSOCIAL CARE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; SCHOOL; SOCIAL ENVIRONMENT; SYMPTOM;

ADOLESCENT; ADULT; DEVELOPED COUNTRIES; HUMANS; MARIJUANA ABUSE; MENTAL DISORDERS; PREVALENCE; PSYCHOLOGY; RISK FACTORS; SOCIAL ENVIRONMENT; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; UNDERACHIEVEMENT;

EID: 33644925868     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2006.01756.x     Document Type: Review

References (98)

1. Hall WD, Pacula RL. Cannabis use and dependence: Public health and public policy. Cambridge: Cambridge University Press, 2003.
2. Fergusson DM, Horword LJ, Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 2002; 97: 1123-1135.
3. Lynskey M, Hall WD. The effects of adolescent cannabis use on educational attainment: A review. Addiction 2000; 96: 433-443.
4. MacLeod J, Oakes R, Copello A et al. The psychosocial consequences of use of cannabis and other illicit drugs: Systematic review of longitudinal, general population studies. Lancet 2004; 363: 1579-1588.
5. Adams IB, Martin BR. Cannabis: Pharmacology and toxicology in animals and humans. Addiction 1996; 91: 1585-1614.
6. Compton DR, Dewey WL, Martin BR. Cannabis dependence and tolerance production. Advances in Alcohol and Substance Abuse 1990; 9: 129-147.
7. Maldonado R. Study of cannabinoid dependence in animals. Pharmacology and Therapeutics 2002; 95: 153-164.
8. Aceto M, Scates S, lowe A, Martin B. Dependence studies on delta-9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. Journal of Pharmacology and Experimental Therapeutics 1996; 278: 1290-1295.
9. Cook SA, Lowe JA, Martin BR. CB1 receptor antagonist precipitates withdrawal in mice exposed to delta9-tetrahydrocannabinol. Journal of Pharmacology and Experimental Therapeutics 1998; 285: 1150-1156.
10. Copeland J, Swift W, Rees V. Clinical profile of participants in a brief intervention program for cannabis use disorder. Journal of Substance Abuse Treatment 2001; 20: 45-52.
11. Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence - a test of the relapse prevention model. Journal of Consulting and Clinical Psychology 1994; 62: 92-99.
12. Swift W, Hall WD, Copeland J. Characteristics of long-term cannabis users in Sydney, Australia. European Addiction Research 1998; 4: 190-197.
13. Wiesbeck GA, Schuckit MA, Kalmijn JA, Tipp JE, Bucholz KK, Smith TL. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction 1996; 91: 1469-1478.
14. Robins LN, Reiger DA, eds. Psychiatric disorders in America: The epidemiological catchment area study. New York: Free Press, 1991.
15. Anthony JC, Warner L, Kessler R. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances and inhalants: Basic findings from the National Comorbidity Survey. Experimental and Clinical Psychopharmacology 1994; 2: 244-268.
16. Hwu HG, Compton WM. Comparison of major epidemiological surveys using the Diagnostic Interview Schedule. International Review of Psychiatry 1994; 6: 309-327.
17. Russell JM, Newman SC, Bland RC. Drug abuse and dependence. Acta Psychiatrica Scandinavica 1994; 89: 54-62.
18. Wells J, Bushnell J, Joyce PR, Oakley-Browne M, Hornblow A. Problems with alcohol, drugs and gambling in Christchurch, New Zealand. In: Abbot M, Evans K, eds. Alcohol and drug dependence and disorders of impulse control. Auckland: Alcohol Liquor Advisory Council, 1992: 3-13.
19. Hall WD, Teesson M, Lynskey M, Degenhardt L. The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey of Mental Health and Well-being. Addiction 1999; 94: 1541-1550.
20. Hall WD, Solowij N, Lemon J. The health and psychological consequences of cannabis use. Canberra: Australian Government Publishing Service, 1994.
21. Brook JS, Cohen P, Whiteman M, Gordon AS. Psychosocial risk factors in the transition from moderate to heavy use or abuse of drugs. In: Glantz MD, ed. Vulnerability to drug abuse. Washington, DC: American Psychological Association, 1992: 359-388.
22. Kandel DB, Davies M. Progression to regular marijuana involvement: phenomenology and risk factors for near-daily use. In: Glantz MD, ed. Vulnerability to drug abuse. Washington, DC: American Psychological Association, 1992: 211-253.
23. Newcomb MD. Understanding the multidimensional nature of drug use and abuse: The role of consumption, risk factors, and protective factors. In: Glantz MD, ed. Vulnerability to drug abuse. Washington, DC: American Psychological Association, 1992: 255-297.
24. Shedler J, Block J. Adolescent drug use and psychological health: A longitudinal inquiry. American Psychologist 1990; 45: 612-630.
25. Budney AJ, Moore BA. Development and consequences of cannabis dependence. Journal of Clinical Pharmacology 2002; 42: 28S-33S.
26. Stephens RS, Babor TF, Kadden R, Miller M. The Marijuana Treatment Project: Rationale, design and participant characteristics. Addiction 2002; 97: 109-124.
27. Crowley TJ, Macdonald MJ, Whitmore EA, Mikulich SK. Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct symptoms and substance use disorders. Drug and Alcohol Dependence 1998; 50: 27-37.
28. Tims FM, Dennis ML, Hamilton N et al. Characteristics and problems of 600 adolescent cannabis abusers in outpatient treatment. Addiction 2002; 97: 46-57.
29. Morral AR, McCaffrey DF, Paddock SM. Reassessing the marijuana gateway effect. Addiction 2002; 97: 1493-1504.
30. Kandel DB. Stages in adolescent involvement in drug use. Science 1975; 190: 912-914.
31. Kandel DB, ed. Stages and pathways of drug involvement: Examining the gateway hypothesis. New York: Cambridge University Press, 2002.
32. Kandel DB. Marijuana users in young adulthood. Archives of General Psychiatry 1984; 41: 200-209.
33. Donnelly N, Hall WD. Patterns of cannabis use in Australia. Canberra: Australian Government Publishing Service, 1994.
34. Donovan JE, Jessor R. Problem drinking and the dimension of involvement with drugs: A Guttman scalogram analysis of adolescent drug use. American Journal of Public Health 1983; 73: 543-552.
35. Kandel DB. Issues of sequencing of adolescent drug use and other problem behaviors. Drugs and Society 1988; 3: 55-76.
36. Cohen S. Drug use: Religion and secularization. American Journal of Psychiatry 1972; 129: 97.
37. Goode E. Marijuana use and the progression to dangerous drugs. In: Miller LL, ed. Marijuana: Effects on human behavior. New York: Academic Press, 1974: 303-338.
38. Wagner FA, Anthony JC. Into the world of illegal drug use: Exposure opportunity and other mechanisms linking the use of alcohol, tobacco, marijuana, and cocaine. American Journal of Epidemiology 2002; 155: 918-925.
39. Fergusson DM, Horwood LJ. Does cannabis use encourage other forms of illicit drug use? Addiction 2000; 95: 505-520.
40. Kaplan HB, Martin SS, Robbins C. Pathways to adolescent drug use: self-derogation, peer influence, weakening of social controls, and early substance use. Journal of Health and Social Behavior 1984; 25: 270-289.
41. Newcomb MD, Bentler PM. Consequences of adolescent drug use: Impact on the lives of young adults. Thousand Oaks, CA: Sage, 1988.
42. Jessor R, Jessor SL. Problem behavior and psychosocial development: A longitudinal study of youth. New York: Academic Press, 1977.
43. Osgood DW, Johnston LD, O'Malley PM, Bachman JG. The generality of deviance in late adolescence and early adulthood. American Sociological Review 1988; 53: 81-93.
44. McGee R, Feehan M. Cannabis use among New Zealand adolescents. New Zealand Medical Journal 1993; 106: 345.
45. Jessor R, Jessor SL. Theory testing in longitudinal research on marijuana use. In: Kandel DB, ed. Longitudinal research on drug use: empirical findings and methodological issues. New York: Wiley, 1978: 41-71.
46. Bailey SL, Flewelling RL, Rachal JV. Predicting continued use of marijuana among adolescents: The relative influence of drug-specific and social context factors. Journal of Health and Social Behavior 1992; 33: 51-66.
47. Hawkins JD, Catalano RF, Miller JY. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. Psychological Bulletin 1992; 112: 64-105.
48. Yamaguchi K, Kandel DB. Patterns of drug use from adolescence to young adulthood: III. Predictors of progression. American Journal of Public Health 1984; 74: 673-681.
49. True WR, Heath AC, Scherrer JF et al. Interrelationship of genetic and environmental influences on conduct disorder and alcohol and marijuana dependence symptoms. American Journal of Medical Genetics 1999; 88: 391-397.
50. Lynskey MT, Heath AC, Bucholz KK, Slutske WS. Escalation of drug use in early-onset cannabis users vs co-twin controls. Journal of the American Medical Association 2003; 289: 427-433.
51. Nahas GG. Keep off the grass. 5th edn. Middlebury, VT: Paul Eriksson, 1990.
52. Gardner EL. Cannabinoid interaction with brain reward systems. In: Nahas G, Sutin KM, Harvey D, Agurell S, eds. Marihuana and medicine. Towa, NJ: Humana Press, 1999: 187-205.
53. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends in Pharmacological Sciences 1999; 20: 287-294.
54. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G. Behavioural sensitization after repeated exposure to [Delta]9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology 2001; 158: 259-266.
55. Lamarque S, Taghzouti K, Simon H. Chronic treatment with [Delta]9-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroin: Implications for vulnerability to drug addiction. Neuropharmacology 2001; 41: 118-129.
56. Lynskey M. An alternative model is feasible, but the gateway hypothesis has not been invalidated: Comments on Morral et al. Addiction 2002; 97: 1505-1507.
57. Polich JM, Ellickson PL, Reuter P, Kahan JP. Strategies for controlling adolescent drug use. Santa Monica, CA: RAND, 1984.
58. Botvin GJ, Scheier LM, Griffin KW. Preventing the onset and developmental progression of adolescent drug use: Implications for the gateway hypothesis. In: Kandel DB, ed. Stages and pathways of drug involvement: Examining the gateway hypothesis. New York: Cambridge University Press, 2002: 115-138.
59. Caulkins JP, Rydell CP, Everingham SMS, Chiesa JR, Bushway S. An ounce of prevention, a pound of uncertainty: The cost-effectiveness of school-based drug prevention programs. Santa Monica, CA: RAND, 1999.
60. Baumrind D, Moselle KA. A developmental perspective on adolescent drug abuse. Advances in Alcohol and Substance Abuse 1985; 4: 41-67.
61. Kandel DB, Davies M, Karus D, Yamaguchi K. The consequences in young adulthood of adolescent drug involvement: An overview. Archives of General Psychiatry 1986; 43: 746-754.
62. Duncan SC, Duncan TE, Biglan A, Ary D. Contributions of the social context to the development of adolescent substance use: A multivariate latent growth modeling approach. Drug and Alcohol Dependence 1998; 50: 57-71.
63. Hundleby JD, Mercer GW. Family and friends as social environments and their relationship to young adolescents' use of alcohol, tobacco, and marijuana. Journal of Marriage and the Family 1987; 49: 151-164.
64. Jessor R. Predicting time of onset of marijuana use: A developmental study of high school youth. Journal of Consulting and Clinical Psychology 1976; 44: 125-134.
65. Kelly D, Balch RW. Social origins and school failure: A re-examination of Cohen's theory of working-class delinquency. Pacific Sociological Review 1971; 14: 413-430.
66. Krohn MD, Lizotte AJ, Perez CM. The interrelationship between substance use and precocious transitions to adult statuses. Journal of Health and Social Behavior 1997; 38: 87-103.
67. Kandel DB. Drug and drinking behavior among youth. Annual Review of Sociology 1980; 6: 235-285.
68. Newcomb MD, Bentler PM. Substance use and abuse among children and teenagers. American Psychologist 1989; 44: 242-248.
69. Rutter M. Longitudinal data in the study of causal processes: Some uses and some pitfalls. In: Rutter M, ed. STudies of psychosocial risk: the power of longitudinal data. Cambridge, UK: Cambridge University Press, 1988: 12-19.
70. Fergusson DM, Lynskey MT, Horwood LJ. The short-term consequences of early onset cannabis use. Journal of Abnormal Child Psychology 1996; 24: 499-512.
71. Ellickson P, Bui K, Bell R, McGuigan KA. Does early drug use increase the risk of dropping out of high school? Journal of Drug Issues 1998; 28: 357-380.
72. Tanner J, Davies S, O'Grady B. Whatever happened to yesterday's rebels? Longitudinal effects of youth delinquency on education and employment. Social Problems 1999; 46: 250-274.
73. Tien AY, Anthony JC. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. Journal of Nervous and Mental Disease 1990; 178: 473-480.
74. Thomas H. A community survey of adverse effects of cannabis use. Drug and Alcohol Dependence 1996; 42: 201-207.
75. Degenhardt L, Hall WD. The association between psychosis and problematical drug use among Australian adults: Findings from the National Survey of Mental Health and Well-being. Psychological Medicine 2001; 31: 659-668.
76. Schneier FR, Siris SG. A review of psychoactive substance use and abuse in schizophrenia: Patterns of drug choice. Journal of Nervous and Mental Disease 1987; 175: 641-652.
77. Smith J, Hucker S. Schizophrenia and substance abuse. British Journal of Psychiatry 1994; 165: 13-21.
78. Warner R, Taylor D, Wright J et al. Substance use among the mentally ill: Prevalence, reasons for use, and effects on illness. American Journal of Orthopsychiatry 1994; 64: 30-39.
79. Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biological Psychiatry 1996; 40: 1155-1163.
80. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophrenia and substance abuse: Implications for treatment. Journal of Consulting and Clinical Psychology 1992; 60: 845-856.
81. Hall WD. Cannabis and psychosis. Drug and Alcohol Review 1998; 17: 433-444.
82. Thornicroft G. Cannabis and psychosis: Is there epidemiological evidence for association? British Journal of Psychiatry 1990; 157: 25-33.
83. Andreasson S, Engstrom A, Allebeck P, Rydberg U. Cannabis and schizophrenia: A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483-1486.
84. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. British Medical Journal 2002; 325: 1199-1201.
85. van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: A longitudinal population-based study. American Journal of Epidemiology 2002; 156: 319-327.
86. Henquet C, Krabbendam L, Spauwen J et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 2005; 330: 11.
87. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. British Medical Journal 2002; 325: 1212-1213.
88. Fergusson DM, Horwood JL, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychological Medicine 2003; 33: 15-21.
89. Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen J. Cannabis use and the expression of psychosis vulnerability in daily life. European Psychiatry 2002; 17: 180s.
90. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophrenia Research 1995; 15: 277-281.
91. D'Souza DC, Cho HS, Perry EB, Krystal JH. Cannabinoid 'model' psychosis, dopamine-cannabinoid interactions and implications for schizophrenia. In: Castle D, Murray R, eds. Marijuana andPmadness: psychiatry and neurobiology. Cambridge: Cambridge University Press, 2004: 142-165.
92. Caspi A, Moffitt TE, Cannon M et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene × environment interaction. Biological Psychiatry 2005; 57: 1117-1127.
93. Hall W, Swift W. The THC content of cannabis in Australia: Evidence and implications. Australian and New Zealand Journal of Public Health 2000; 24: 503-508.
94. European Monitoring Centre for Drugs and Drug Addiction. An Overview of Cannabis Potency in Europe. Lisbon: EMCDDA, 2004.
95. ElSohly MA, Ross SA. Quarterly report: Potency monitoring project. Report 69: January 1, 1999-March 31, 1999. Oxford, MS: National Center for the Development of Natural Products, University of Mississippi, 1999.
96. ElSohly MA, Ross SA, Mehmedic Z, Arafat R, Yi B, Banahan BF. Potency trends of delta(9)-THC and other cannabinoids in confiscated marijuana from 1980-1997. Journal of Forensic Sciences 2000; 45: 24-30.
97. Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug and Alcohol Review 2005; 24: 39-48.
98. Hall WD, Degenhardt L, Teesson M. Cannabis use and psychotic disorders: an update. Drug and Alcohol Review 2004; 23: 433-443.